UNSPSC 51111807: Leuprolide

This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EFY6W0M8TG. European Medicines Agency schedules Leuprolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08449MIG. Leuprolide generally arises in the molecular formula C59H84N16O12. The term 'leuprolide' is a European Pharmacopoeia designation. As of Q4 2014, LEUPROLIDE remains the US FDA Preferred Term for this commodity.

Leuprolide bears US NLM identifiers UMLS ID C0085272 and NCI Concept Code C62042. SMILES: O=C(N1C(CCC1)C(=O)NCC)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1[NH]CNC1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)CC(C)C)CC(C)C)CCC/N=C(/N)N.

UNSPSC 51111807 Leuprolide, a Commodity code, encompasses pharmaceutical supply agreements through state and local cooperative purchasing vehicles, where government health agencies and facilities procure branded and generic medications for distribution across their systems. State and local governments source leuprolide — a hormone-modulating injectable used in prostate cancer and endometriosis treatment — either as a named-line item within broader pharmaceutical frameworks or through multi-source generic pharmaceutical contracts that bundle numerous drugs under single cooperative agreements. Cooperative purchasing alliances, state health departments, and participating local government health facilities are the primary issuing bodies under this code, leveraging group purchasing power to negotiate volume pricing and standardized supply terms with manufacturers and authorized pharmaceutical wholesalers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, including Oregon. Awarded vendors must supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and meet cGMP and Drug Supply Chain Security Act compliance requirements. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for contract term, and 5 percent each on administrative fee format compliance, EDI capability, and 3 percent administrative fee agreement. The contract term is two years for new vendors with optional extensions through June 30, 2028 for incumbents. Vendors must maintain commercial general liability of $5 million per occurrence and network security and privacy liability of $2 million, with performance penalties ranging from $200 to $1,500 per violation for late reporting or missed timelines.